ErbB2-Driven Breast Cancer Cell Invasion Depends on a Complex Signaling Network Activating Myeloid Zinc Finger-1-Dependent Cathepsin B Expression

Molecular Cell

Volumn 45, Issue 6, 2012, Pages 764-776

  Rafn, Bo ^a   Nielsen, Christian Friberg ^a   Andersen, Sofie Hagel ^a   Szyniarowski, Piotr ^a   Corcelle Termeau, Elisabeth ^a   Valo, Erkka ^b   Fehrenbacher, Nicole ^a   Olsen, Charlotta Johanne ^a,c   Daugaard, Mads ^a   Egebjerg, Christina ^a   Bøttzauw, Trine ^a   Kohonen, Pekka ^d   Nylandsted, Jesper ^a   Hautaniemi, Sampsa ^b   Moreira, José ^a,c   Jäättelä, Marja ^a   Kallunki, Tuula ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Institute of Cancer Biolog   (Denmark)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN L; EPIDERMAL GROWTH FACTOR RECEPTOR 2; P21 ACTIVATED KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER 1 PROTEIN;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRON; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CATHEPSIN B; CATHEPSIN L; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM INVASIVENESS; P21-ACTIVATED KINASES; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C-ALPHA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTOR, ERBB-2; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION;

EID: 84859085199     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2012.01.029     Document Type: Article

References (42)

1. Abboud-Jarrous G., Atzmon R., Peretz T., Palermo C., Gadea B.B., Joyce J.A., Vlodavsky I. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J. Biol. Chem. 2008, 283:18167-18176.
2. Abo A., Qu J., Cammarano M.S., Dan C., Fritsch A., Baud V., Belisle B., Minden A. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J. 1998, 17:6527-6540.
3. Bosc D.G., Goueli B.S., Janknecht R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 2001, 20:6215-6224.
4. Collette J., Ulku A.S., Der C.J., Jones A., Erickson A.H. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int. J. Cancer 2004, 112:190-199.
5. De Keulenaer G.W., Doggen K., Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res. 2010, 106:35-46.
6. Dehvari N., Isacsson O., Winblad B., Cedazo-Minguez A., Cowburn R.F. Presenilin regulates extracellular regulated kinase (Erk) activity by a protein kinase C alpha dependent mechanism. Neurosci. Lett. 2008, 436:77-80.
7. Dietrich N., Thastrup J., Holmberg C., Gyrd-Hansen M., Fehrenbacher N., Lademann U., Lerdrup M., Herdegen T., Jäättelä M., Kallunki T. JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways. Cell Death Differ. 2004, 11:301-313.
8. Egeblad M., Mortensen O.H., Jäättelä M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int. J. Cancer 2001, 94:185-191.
9. Fehrenbacher N., Bastholm L., Kirkegaard-Sørensen T., Rafn B., Bøttzauw T., Nielsen C., Weber E., Shirasawa S., Kallunki T., Jäättelä M. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res. 2008, 68:6623-6633.
10. Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6:60-64.
11. Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., Hanahan D., Joyce J.A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20:543-556.
12. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16:1647-1655.
13. Holbro T., Hynes N.E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 2004, 44:195-217.
14. Hromas R., Morris J., Cornetta K., Berebitsky D., Davidson A., Sha M., Sledge G., Rauscher F. Aberrant expression of the myeloid zinc finger gene, MZF-1, is oncogenic. Cancer Res. 1995, 55:3610-3614.
15. Hsieh Y.H., Wu T.T., Tsai J.H., Huang C.Y., Hsieh Y.S., Liu J.Y. PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochem. Biophys. Res. Commun. 2006, 339:217-225.
16. Javelaud D., Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005, 24:5742-5750.
17. Jedeszko C., Sloane B.F. Cysteine cathepsins in human cancer. Biol. Chem. 2004, 385:1017-1027.
18. Joyce J.A., Baruch A., Chehade K., Meyer-Morse N., Giraudo E., Tsai F.Y., Greenbaum D.C., Hager J.H., Bogyo M., Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5:443-453.
19. Ke Z., Lin H., Fan Z., Cai T.Q., Kaplan R.A., Ma C., Bower K.A., Shi X., Luo J. MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2. Int. J. Cancer 2006, 119:8-16.
20. Kirkegaard T., Jäättelä M. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta 2009, 1793:746-754.
21. Kobayashi H., Schmitt M., Goretzki L., Chucholowski N., Calvete J., Kramer M., Günzler W.A., Jänicke F., Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J. Biol. Chem. 1991, 266:5147-5152.
22. Liu Y., Chen N., Cui X., Zheng X., Deng L., Price S., Karantza V., Minden A. The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis. Oncogene 2010, 29:5883-5894.
23. Magnifico A., Albano L., Campaner S., Campiglio M., Pilotti S., Ménard S., Tagliabue E. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res. 2007, 67:5308-5317.
24. Moasser M.M. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007, 26:6577-6592.
25. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
26. Moncrieff C.L., Bailey M.E., Morrison N., Johnson K.J. Cloning and chromosomal localization of human Cdc42-binding protein kinase beta. Genomics 1999, 57:297-300.
27. Mudduluru G., Vajkoczy P., Allgayer H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol. Cancer Res. 2010, 8:159-169.
28. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232:123-138.
29. Ogawa H., Murayama A., Nagata S., Fukunaga R. Regulation of myeloid zinc finger protein 2A transactivation activity through phosphorylation by mitogen-activated protein kinases. J. Biol. Chem. 2003, 278:2921-2927.
30. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
31. Sáez R., Molina M.A., Ramsey E.E., Rojo F., Keenan E.J., Albanell J., Lluch A., García-Conde J., Baselga J., Clinton G.M. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. 2006, 12:424-431.
32. Sardiello M., Palmieri M., di Ronza A., Medina D.L., Valenza M., Gennarino V.A., Di Malta C., Donaudy F., Embrione V., Polishchuk R.S., et al. A gene network regulating lysosomal biogenesis and function. Science 2009, 325:473-477.
33. Scaltriti M., Rojo F., Ocaña A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Ramon y Cajal S., Arribas J., Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 2007, 99:628-638.
34. Schmidt-Hansen B., Ornås D., Grigorian M., Klingelhöfer J., Tulchinsky E., Lukanidin E., Ambartsumian N. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004, 23:5487-5495.
35. Sloane B.F., Moin K., Sameni M., Tait L.R., Rozhin J., Ziegler G. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J. Cell Sci. 1994, 107:373-384.
36. Thomssen C., Schmitt M., Goretzki L., Oppelt P., Pache L., Dettmar P., Jänicke F., Graeff H. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin. Cancer Res. 1995, 1:741-746.
37. Ursini-Siegel J., Schade B., Cardiff R.D., Muller W.J. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 2007, 7:389-397.
38. Vasiljeva O., Papazoglou A., Krüger A., Brodoefel H., Korovin M., Deussing J., Augustin N., Nielsen B.S., Almholt K., Bogyo M., et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006, 66:5242-5250.
39. Xia W., Liu L.H., Ho P., Spector N.L. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004, 23:646-653.
40. Yan S., Berquin I.M., Troen B.R., Sloane B.F. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol. 2000, 19:79-91.
41. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
42. Yong H.Y., Kim I.Y., Kim J.S., Moon A. ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling. Int. J. Oncol. 2010, 36:501-507.